RxDoctor Payments Data

Roger Lane, MD

Internal Medicine · Solvang, CANPI 1154424240

Payments from drug & device makers

$268in general payments, 2019–2025

Across 14 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$66
  • Pfizer$44
  • Johnson & Johnson$41
  • AbbVie$33
  • Esperion Therapeutics, Inc.$20
  • Boehringer Ingelheim$20
  • plus $44 from 3 others
$2,764in research payments, 2019–2025

Across 8 payments — averaging $345.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$3K

What the payments were for

  • Food & beverage$268100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$268 in reported general payments places this provider in the 55th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$397,051
Medicare patients
544
Services billed
4,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$93,180
JardianceEmpagliflozin50$55,509
XareltoRivaroxaban61$46,340
OzempicSemaglutide19$17,904
Breo ElliptaFluticasone/Vilanterol15$9,316
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$7,803
Atorvastatin Calcium650$6,823
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,391
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,418
Levothyroxine Sodium296$3,304
Losartan Potassium315$3,285
Tamsulosin Hcl180$2,842
Rosuvastatin Calcium176$2,773
Ezetimibe47$2,589
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$93,18087 claims
Boehringer IngelheimJardiance$20$55,50950 claims
Johnson & JohnsonXarelto$41$46,34061 claims
AbbVieSynthroid$33$2,03125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Solvang

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →